1) Hemato-oncological imaging : Importance of hybrid procedures.
Mayerhoefer ME,
Haug A.
Radiologe.
2016 Jul;56(7):597-604.
doi: 10.1007/s00117-016-0126-6.
German.
2) The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma.
Brioli A,
Morgan GJ,
Durie B,
Zamagni E.
Expert Rev Hematol.
2014 Feb;7(1):13-6.
doi: 10.1586/17474086.2014.873347.
3) Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis,
follow-up and evaluation of disease activity and extent in multiple myeloma.
Dutoit JC,
Vanderkerken MA,
Verstraete KL.
Eur J Radiol.
2013 Sep;82(9):1444-52.
doi: 10.1016/j.ejrad.2013.04.012.
4) Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging.
Lin C,
Luciani A,
Belhadj K,
Deux JF,
Kuhnowski F,
Maatouk M,
Beaussart P,
Cuenod CA,
Haioun C,
Rahmouni A.
Radiology.
2010 Feb;254(2):521-31.
doi: 10.1148/radiol.09090629.
5) Whole-body MRI for the staging and follow-up of patients with metastasis.
Schmidt GP,
Reiser MF,
Baur-Melnyk A.
Eur J Radiol.
2009 Jun;70(3):393-400.
doi: 10.1016/j.ejrad.2009.03.045.
Review.
6) Patients with plasma cell disorders examined at whole-body dynamic contrast-enhanced MR imaging: initial experience.
Lin C,
Luciani A,
Belhadj K,
Maison P,
Vignaud A,
Deux JF,
Zerbib P,
Pigneur F,
Itti E,
Kobeiter H,
Haioun C,
Rahmouni A.
Radiology.
2009 Mar;250(3):905-15.
doi: 10.1148/radiol.2503081017.
7) Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP,
Kramer H,
Reiser MF,
Glaser C.
Top Magn Reson Imaging.
2007 Jun;18(3):193-202.
Review.